Kamila Castro1,2,3, Diego Baronio1,3, Ingrid Schweigert Perry2,4, Rudimar Dos Santos Riesgo1,3,5, Carmem Gottfried1. 1. a Translational Research Group in Autism Spectrum Disorder (GETTEA) , Porto Alegre , Brazil. 2. b Food and Nutrition Research Center , Hospital de Clínicas de Porto Alegre , Brazil. 3. c Postgraduate Program in Child and Adolescent Health , Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil. 4. d Postgraduate Program in Public Health, Academic Unit of Health Science , Universidade do Extremo Sul Catarinense , Criciúma , SC , Brazil. 5. e Child Neurology Unit, Hospital de Clínicas de Porto Alegre , Brazil.
Abstract
OBJECTIVES: Autism spectrum disorder (ASD) is characterized by impairments in social interaction and communication, and by restricted repetitive behaviors and interests. Its etiology is still unknown, but different environmental factors during pregnancy, such as exposure to valproic acid (VPA), are associated with high incidence of ASD in children. In this context, prenatal exposure to VPA in rodents has been used as a reliable model of ASD. Ketogenic diet (KD) is an alternative therapeutic option for refractory epilepsy; however, the effects of this approach in ASD-like behavior need to be evaluated. We conducted a behavioral assessment of the effects of KD in the VPA model of autism. METHODS: Pregnant animals received a single-intraperitoneal injection of 600 mg/kg VPA, and their offspring were separated into four groups: (1) control group with standard diet (C-SD), (2) control group with ketogenic diet (C-KD), (3) VPA group with standard diet (VPA-SD), and (4) VPA group with ketogenic diet (VPA-KD). RESULTS: When compared with the control group, VPA animals presented increased social impairment, repetitive behavior and higher nociceptive threshold. Interestingly, the VPA group fed with KD presented improvements in social behavior. These mice displayed higher scores in sociability index and social novelty index when compared with the SD-fed VPA mice. DISCUSSION: VPA mice chronically exposed to a KD presented behavioral improvements; however, the mechanism by which KD improves ASD-like features needs to be further investigated. In conclusion, the present study reinforces the potential use of KD as a treatment for the core deficits of ASD.
OBJECTIVES:Autism spectrum disorder (ASD) is characterized by impairments in social interaction and communication, and by restricted repetitive behaviors and interests. Its etiology is still unknown, but different environmental factors during pregnancy, such as exposure to valproic acid (VPA), are associated with high incidence of ASD in children. In this context, prenatal exposure to VPA in rodents has been used as a reliable model of ASD. Ketogenic diet (KD) is an alternative therapeutic option for refractory epilepsy; however, the effects of this approach in ASD-like behavior need to be evaluated. We conducted a behavioral assessment of the effects of KD in the VPA model of autism. METHODS: Pregnant animals received a single-intraperitoneal injection of 600 mg/kg VPA, and their offspring were separated into four groups: (1) control group with standard diet (C-SD), (2) control group with ketogenic diet (C-KD), (3) VPA group with standard diet (VPA-SD), and (4) VPA group with ketogenic diet (VPA-KD). RESULTS: When compared with the control group, VPA animals presented increased social impairment, repetitive behavior and higher nociceptive threshold. Interestingly, the VPA group fed with KD presented improvements in social behavior. These mice displayed higher scores in sociability index and social novelty index when compared with the SD-fed VPAmice. DISCUSSION: VPAmice chronically exposed to a KD presented behavioral improvements; however, the mechanism by which KD improves ASD-like features needs to be further investigated. In conclusion, the present study reinforces the potential use of KD as a treatment for the core deficits of ASD.
Authors: Ryan W Y Lee; Michael J Corley; Alina Pang; Gaye Arakaki; Lisa Abbott; Michael Nishimoto; Rob Miyamoto; Erica Lee; Susan Yamamoto; Alika K Maunakea; Annette Lum-Jones; Miki Wong Journal: Physiol Behav Date: 2018-02-05
Authors: Joseph C Boktor; Mark D Adame; Destanie R Rose; Cynthia M Schumann; Karl D Murray; Melissa D Bauman; Milo Careaga; Sarkis K Mazmanian; Paul Ashwood; Brittany D Needham Journal: Mol Psychiatry Date: 2022-08-26 Impact factor: 13.437
Authors: Pamela R Westmark; Alejandra Gutierrez; Aaron K Gholston; Taralyn M Wilmer; Cara J Westmark Journal: Neurochem Int Date: 2020-01-17 Impact factor: 3.921
Authors: Jessica J Walsh; Pierre Llorach; Daniel F Cardozo Pinto; Wendy Wenderski; Daniel J Christoffel; Juliana S Salgado; Boris D Heifets; Gerald R Crabtree; Robert C Malenka Journal: Neuropsychopharmacology Date: 2021-07-08 Impact factor: 8.294